# rheumatoid arthritis - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: synovial tissue
- Comparison or endpoint: rheumatoid arthritis versus normal control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: d868ce3efb219458b8d5ddb7b123eef3f2b718852ba0ede74f2a02e9181db293
- Response HTTP status: 200
- Prompt tokens: 15869
- Completion tokens: 6036
- Reasoning tokens: 2110
- Total tokens: 21905
- API requests reported: 1
- Elapsed seconds: 67.426
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 984.622
- Question handoff seconds: 999.892
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: MiniMax

---
<think>The user wants a multidimensional interpretation of transcriptomic data from rheumatoid arthritis (RA) synovial tissue comparing RA vs normal control. Let me carefully analyze the input.

Key observations from the statistical ledger:
1. ALL 100 selected genes are DOWNREGULATED in RA vs normal
2. Effect sizes range from log2FC = -2.279 to -5.102
3. All have extremely significant P values and FDR (FDR ≤ 0.05 for all 100)
4. The gene list contains a striking pattern:
   - Many lncRNAs and uncharacterized loci (LOC entries, LINC, lncRNAs)
   - Many microRNAs (MIR series)
   - Many snoRNAs/snRNAs (SNORD, SCARNA, RNA5-8SN)
   - Many mucins (MUC5B, MUC6, MUC12)
   - Some structural proteins (CROCC, CDHR5, GJC2, GIGYF1)
   - Some zinc finger proteins (ZNF316, ZNF219, ZNF444, ZNF580, etc.)
   - Some regulatory/signaling proteins (SCRIB, APC2, ARVCF, ARHGAP33, etc.)

This is a striking pattern - an ALL-downregulated signature with no upregulated genes. This is unusual for RA synovial tissue which typically shows strong inflammatory upregulation (IL6, TNF, MMPs, chemokines, etc.). This suggests:

1. The data may represent a specific cell type or sorted population rather than whole tissue
2. The "normal control" may have higher expression of these tissue-specific/specialized genes (e.g., mucins, structural ciliary proteins like CROCC)
3. Many of these genes are highly tissue-specific (mucins → epithelial; CROCC → ciliated cells; GRIFIN → lens/cornea; SCART1 → lymphoid/epithelial)
4. The pattern looks like a LOSS of specialized epithelial/ciliated/mucosal cell identity in RA synovium, or rather, the "normal" synovial control includes many cell types that are lost/reduced in RA tissue

Wait - this is synovial tissue. The presence of mucins (MUC5B, MUC6, MUC12), CROCC (ciliary rootlet), GRIFIN (lens/cornea protein - unusual!), CDHR5 (gut epithelial cadherin), SCART1 (scavenger receptor), and many LOC genes is highly unusual for synovium.

The recurrent KEGG modules from RAG were: Ribosome biogenesis in eukaryotes, Ribosome, Hippo signaling pathway - but the STRING edges only show 20 edges. With 100 genes mostly uncharacterized (LOC, LINC, MIR, SNORD), STRING evidence is limited.

The recurrent pathway/ontology modules show:
- molecular_function (44 genes)
- biological_process (35 genes)
- cellular_component (34 genes)
- protein binding (34)
- nucleus (9)
- plasma membrane (7)
- membrane (6)
- cytoplasm (5)

The network evidence shows:
- MUC1 hub: MUC12, MUC5B, MUC6
- CASP2 hub: NOL3, PIDD1
- COMT hub: ARVCF, DRD4
- CTNNB1 hub: APC2, ARVCF
- LRRC45 hub: CROCC, CROCC2
- MUC2 hub: MUC12, MUC6
- MUC5AC hub: MUC5B, MUC6
- MUC7 hub: MUC5B, MUC6

So there's a clear mucin network (MUC5B/MUC6/MUC12 all downregulated) and a Hippo/Wnt signaling module (APC2/ARVCF interact with CTNNB1; SCRIB in planar cell polarity).

The key biological programs I can identify:

1. **Loss of epithelial/mucosal barrier identity** - MUC5B, MUC6, MUC12 (mucin network), CDHR5 (epithelial cadherin), SCART1, GRIFIN. These are characteristic of mucosal/epithelial tissues. In synovium this would suggest loss of specialized lining cells or fibroblast subpopulations.

2. **Loss of ciliary/structural architecture** - CROCC, CROCC2, CROCCP2 (ciliary rootlet proteins), GJC2 (gap junction, connexin 47 - typically CNS myelin/oligodendrocyte), PLEKHH3 (pleckstrin homology domain in ciliated cells), CDHR5.

3. **Planar cell polarity / Hippo-Wnt signaling dysregulation** - SCRIB (scribble, PCP component), APC2 (Wnt regulator), ARVCF (catenin family), ARHGAP33 (RhoGAP), CTNNB1 interactions. The Hippo signaling pathway was flagged by KEGG.

4. **Non-coding RNA deregulation** - 16+ microRNAs (MIR937, MIR3154, MIR3183, etc.), SNORD167, SCARNA17, several lncRNAs (PCGF3-AS1, IRAIN, etc.), snoRNAs. These may reflect broad epigenetic/post-transcriptional dysregulation.

5. **Cell death/apoptosis signaling** - PIDD1 (p53-induced death domain), NOL3 (apoptosis repressor), CASP2 network. SH2B1 (signaling adaptor).

The CRITICAL LIMITATION: This dataset is highly atypical for an RA synovial study:
- No upregulated genes at all
- Many tissue-inappropriate genes (mucins, ciliary proteins, GRIFIN which is lens-specific)
- Many LOC/uncharacterized transcripts
- The KEGG enrichment (ribosome, ribosome biogenesis) seems mismatched to the gene content

This raises serious concerns:
1. **Tissue/cell composition confounding** - The "normal" synovium may contain cell types (epithelial, mucosal, ciliated) not actually present in RA synovium. OR the RA samples are depleted of these cells.
2. **Reference/tissue mismatch** - The expression pattern suggests comparison with a non-synovial tissue (perhaps gut mucosa, respiratory mucosa, or a contaminated "normal" reference).
3. **Data quality** - The pattern of LOC genes, snoRNAs, and miRNAs may indicate low-complexity RNA-seq or non-coding RNA contamination.

Let me structure my answer:

I need to follow the principles:
1. Don't be overly speculative
2. Distinguish direct evidence (uploaded) from external annotation
3. State no external cohort validation
4. Discuss data quality concerns
5. Provide 5 core programs, key genes, validation priorities, limitations
6. No external validation is available - must state this

Let me draft the response:

### Overall Biological Interpretation
The transcriptomic signature is dominated by 100 downregulated genes (log2FC from -2.28 to -5.10), all with FDR << 0.001. Strikingly, no upregulated genes reached significance. The downregulated set is enriched in:
- Tissue-restricted structural/secretory genes (mucins, ciliary proteins, epithelial cadherins)
- Cell polarity and Hippo/Wnt pathway components
- Multiple non-coding RNAs (miRNAs, snoRNAs, lncRNAs)
- Many uncharacterized LOC transcripts

In the context of RA synovial tissue vs normal control, this unidirectional downregulation pattern is biologically atypical. Established RA synovial transcriptomics typically shows strong upregulation of inflammatory cytokines (IL6, TNF, IL1B), chemokines, MMPs, and immune infiltrate signatures. The absence of any such canonical inflammatory signature here is a major red flag for either:
(a) Tissue/cell-composition confounding (e.g., normal reference tissue contains specialized cell types absent in inflamed RA)
(b) Dataset artefact (low-complexity library, contamination, or non-standard reference)

### Core Biological Programs (max 5)

I'll select programs based on the strongest multi-gene evidence:

1. Mucin/mucosal barrier loss
2. Ciliary/structural architecture loss (Hippo/PCP signaling)
3. Cell death/apoptosis regulation
4. Non-coding RNA/post-transcriptional dysregulation
5. Zinc finger/transcriptional regulator loss

Let me now write the full response.

I need to keep this evidence-grounded and avoid making claims I can't support. The data quality concerns are central.

Actually let me also note: the KEGG pathway analysis cited (Ribosome biogenesis, Ribosome, Hippo signaling) was provided in the batch but the actual gene content doesn't strongly match ribosome biology. So even the KEGG call seems off.

Let me check what STRING evidence exists:
- MUC1 hub (MUC12, MUC5B, MUC6)
- CASP2 hub (NOL3, PIDD1)
- COMT hub (ARVCF, DRD4)
- CTNNB1 hub (APC2, ARVCF)
- LRRC45 hub (CROCC, CROCC2)
- MUC2/MUC5AC/MUC7 hubs all converge on the mucin cluster

These STRING relationships suggest:
- The mucin genes form a network (likely pathway co-membership, possibly co-expression rather than direct physical interaction)
- The ciliary proteins (CROCC/CROCC2) interact via LRRC45
- ARVCF connects to APC2 via CTNNB1 (catenin family)
- PIDD1 connects to NOL3 via CASP2 (apoptosis axis)

For the validation priorities:
1. Validate the data integrity - this is the most important given the suspicious pattern
2. Validate the mucin loss in RA synovium (potential biomarker/composition check)
3. Validate the Hippo/Wnt/PCP signaling module (mechanistic)
4. Validate cell polarity and apoptosis interactions
5. Confirm/refute the inflammatory signature absence (composition check)

Let me structure the final response now. I should be direct about the data quality concern at the top, then proceed with the analysis.</think>

## Data-Quality Warning (must precede interpretation)

The uploaded RA vs. normal synovial signature is **monodirectional and content-atypical**:

- All 100 selected genes are **downregulated** (log2FC range −2.28 to −5.10); zero upregulated genes passed significance.
- The FDR and P values are uniformly extreme (FDR 8.8e-54 to 4.3e-35), a pattern that is statistically "too clean" and that is not what established RA synovial transcriptomes look like (those are dominated by IL6/TNF/IL1B/MMP/chemokine *upregulation*).
- The gene content is dominated by **mucins (MUC5B/MUC6/MUC12)**, **ciliary rootlet proteins (CROCC/CROCC2/CROCCP2)**, the **lens/corneal protein GRIFIN**, gut **CDHR5**, the CNS connexin **GJC2**, dozens of **unannotated LOC/lncRNA loci**, and a large set of **miRNAs/snoRNAs/snRNAs**. Many of these are not normally considered core synovial transcripts.
- Independent-cohort replication: **none provided** (status=not_available). Pathway/ontology records, STRING edges, GTEx tissue calls, and literature coverage are *contextual annotation only* — they do not constitute replication and cannot rescue a suspicious signature.

**Therefore, every interpretation below is conditional on the assumption that the underlying counts are technically valid and that the comparator tissue truly represents normal synovium.** This caveat dominates the entire downstream analysis.

---

## 1. Overall Biological Interpretation

If the data are taken at face value, the dominant theme in RA synovium is the **loss of a tissue-identity/specialized-architecture program** rather than the gain of a classic inflammatory program. The downregulated set clusters into four recognizable themes:

1. **Mucosal/epithelial barrier transcripts** (mucin network, CDHR5, SCART1) — implying loss of barrier-type or mucin-secreting cell identity.
2. **Ciliary and structural polarity transcripts** (CROCC/CROCC2/CROCCP2, GJC2, PLEKHH3, SCRIB, APC2, ARVCF) — implying disruption of apical/planar cell polarity and Hippo/Wnt-cross-regulated cytoskeletal architecture.
3. **Apoptosis/cell-death regulators** (PIDD1, NOL3, CASP2-anchored subnetwork) — altered survival/apoptotic tone.
4. **Broad non-coding-RNA and uncharacterized transcript loss** (multiple MIRs, SNORD/SCARNA/RNA5-8SN family members, PCGF3-AS1, IRAIN, CXXC5-AS1, DM1-AS, TBX2-AS1, TNK2-AS1, ARHGEF17-AS1, etc.) — consistent with a generalized loss of lineage-restricted or differentiation-associated non-coding transcripts.

The *absence* of canonical RA inflammatory mediators (IL6, TNF, IL1B, CCL2, MMP1/3/13, CXCL8/10) from this list is a major interpretive caveat — see §6.

---

## 2. Core Biological Programs (≤5)

### Program A — Mucin/mucosal-barrier identity loss
- **Direction:** all downregulated (log2FC −3.85 to −4.43).
- **Supporting genes:** MUC5B, MUC6, MUC12.
- **Standardized annotation:** Mucin family; GO:0005576 extracellular region / GO:0030246 carbohydrate binding; KEGG not specifically enriched for mucins in the batch.
- **Why these genes:** Three mucins, each independently downregulated at FDR < 1e-39, form a STRING-connected subnetwork anchored on MUC1/MUC2/MUC5AC/MUC7 hubs (network evidence: pathway co-membership / co-annotation, not direct physical binding).
- **Evidence & limitations:** Strong *internal* statistical evidence (3 concordant mucins, all log2FC ≈ −4). External evidence for mucin expression in normal synovium is weak — mucins are characteristic of epithelial/mucosal tissues (airway, gut, salivary), so this pattern is more consistent with a **tissue-composition signature** of the reference than with a meaningful RA mechanism. **Strength:** strong cohort-only. **Limitation:** biologically incongruent with synovial tissue identity.

### Program B — Planar cell polarity / Hippo-Wnt signaling & ciliary architecture
- **Direction:** all downregulated (log2FC −2.41 to −4.99).
- **Supporting genes:** SCRIB, APC2, ARVCF, ARHGAP33, PPP1R12C, CROCC, CROCC2, CROCCP2, GJC2, PLEKHH3.
- **Standardized annotation:** KEGG Hippo signaling pathway; GO planar cell polarity / ciliary / cytoskeletal terms; STRING edges connect ARVCF↔CTNNB1, CROCC/CROCC2↔LRRC45, and SCRIB to ARHGEF7/VANGL2/LLGL1/GIT1/UBE3A (high-confidence physical/functional interactions).
- **Why these genes:** SCRIB is a core PCP/Hippo scaffold; APC2 and ARVCF are catenin-family/Wnt regulators; ARHGAP33 and PPP1R12C are Rho/cytoskeletal regulators; CROCC/CROCC2 are ciliary rootlet coiled-coil proteins. The STRING network gives direct physical/functional evidence for SCRIB (high-confidence interactors) and ARVCF (medium-confidence, including CTNNB1), while the others are pathway co-membership or co-annotation evidence.
- **Evidence & limitations:** Directionally coherent multi-gene signal supported by STRING protein-interaction data for SCRIB and ARVCF specifically. **Limitation:** ciliary/PCP biology is not a canonical RA axis; whether this reflects real fibroblast polarization loss vs. contamination of the "normal" comparator with ciliated/mucosal cells is not resolvable from the input.

### Program C — Apoptosis / cell-death regulatory tone
- **Direction:** all downregulated (log2FC −2.45 to −2.89).
- **Supporting genes:** PIDD1, NOL3.
- **Standardized annotation:** STRING network anchored on CASP2 (death receptor / PIDDosome axis); GO apoptosis terms.
- **Why these genes:** PIDD1 is a p53-induced death-domain protein that activates CASP2; NOL3 (ARC) is an apoptosis repressor. The STRING CASP2 hub ties these two together as **pathway co-membership**, not direct physical binding.
- **Evidence & limitations:** Internal signal is two genes; mechanism-wise, it is internally consistent but very narrow. External cohort validation is absent.

### Program D — Non-coding RNA / post-transcriptional dysregulation
- **Direction:** all downregulated (log2FC −2.97 to −5.10).
- **Supporting genes:** MIR937, MIR1301, MIR3154, MIR3183, MIR3615, MIR4492, MIR4665, MIR4730, MIR4763, MIR647, MIR6821; SNORD167, SCARNA17, RNA5-8SN2/3/4; lncRNAs PCGF3-AS1, CXXC5-AS1, IRAIN, DM1-AS, TBX2-AS1, TNK2-AS1, ARHGEF17-AS1, LINC00685, LINC01786; SCAF1 (spliceosome-associated).
- **Standardized annotation:** GO ncRNA processing / RNA binding; Reactome generic terms; KEGG ribosome biogenesis flagged but mostly because of snoRNA/5.8S-rRNA-family hits.
- **Why these genes:** A coordinated downregulation of >10 miRNAs, multiple C/D-box snoRNAs, and several lncRNAs is statistically striking but mechanistically heterogeneous.
- **Evidence & limitations:** Statistical strength is high; biological interpretation is weak because these loci are largely uncharacterized and no literature links them directly to RA synovium. MIR647 has literature context in *lung cancer* (PMID 30349310), not RA — context-mismatch. **MIR647 in RA synovium = insufficient evidence.**

### Program E — Transcription factor / chromatin regulator loss
- **Direction:** all downregulated (log2FC −2.34 to −3.04).
- **Supporting genes:** ZNF316, ZNF219, ZNF444, ZNF580, FLYWCH1, CBX7, SCAF1, PAGR1, SH2B1, SIX5, TNRC18, EXD3.
- **Standardized annotation:** GO protein binding / nucleus; CBX7 is a Polycomb PRC1 component (functional annotation); SH2B1 is an adaptor (JAK/STAT-adjacent).
- **Why these genes:** A cluster of zinc-finger TFs and Polycomb-related chromatin factors losing expression together. CBX7 (PRC1) is the most mechanistically interpretable member.
- **Evidence & limitations:** Internal direction-only signal; no STRING/reactome evidence specifically linking these into one functional complex. **Hypothesis level only.**

---

## 3. Key Genes / Interaction Modules (≤10)

| # | Gene | log2FC (RA vs. normal) | Program | Relationship type (evidence) |
|---|------|-----------------------|---------|------------------------------|
| 1 | **SCRIB** | −3.24 | B (PCP/Hippo) | STRING physical/functional high-confidence interactors ARHGEF7 (0.997), VANGL2 (0.996), GIT1 (0.983), LLGL1 (0.964), UBE3A (0.980) — **direct physical/functional interaction** supported. |
| 2 | **ARVCF** | −3.46 | B (Wnt/PCP) | STRING CTNNB1 (0.804), COMT (0.897), ERBIN (0.831), FMR1 (0.797) — **physical interaction evidence**; functions as a catenin. |
| 3 | **APC2** | −3.02 | B (Wnt) | STRING CTNNB1 network — **co-complex / pathway co-membership** with ARVCF (not direct physical binding of APC2 itself). |
| 4 | **MUC5B / MUC6 / MUC12** | −4.27 to −4.43 | A (mucin) | STRING MUC1/MUC2/MUC5AC/MUC7 hubs — **pathway co-membership / co-annotation**, not direct physical binding among the mucins themselves. |
| 5 | **CROCC / CROCC2 / CROCCP2** | −2.89 to −4.99 | B (ciliary) | STRING LRRC45 hub — **co-membership / co-annotation**; paralog relationship. |
| 6 | **PIDD1 + NOL3** | −2.89 / −2.45 | C (apoptosis) | STRING CASP2 hub — **pathway co-membership** in the PIDDosome/caspase-2 axis; no direct PIDD1↔NOL3 physical binding shown. |
| 7 | **CBX7** | −2.41 | E (Polycomb) | Functional annotation only; **pathway co-membership** with PRC1. |
| 8 | **ARHGAP33** | −3.20 | B (Rho) | Functional co-membership with Rho/cytoskeletal regulation. |
| 9 | **GIGYF1** | −2.88 | E (translation/insulin signaling) | Functional co-membership with GIGYF1/2 complex; no STRING evidence. |
| 10 | **MIR647** (representative ncRNA) | −3.83 | D (ncRNA) | Literature context is **non-RA (NSCLC)** — context-mismatch, **insufficient evidence** for RA. |

Co-expression, pathway co-membership, and literature co-occurrence are **not** treated as direct physical interactions above.

---

## 4. Validation Priorities (≤5)

1. **Confounding / composition check — Re-derive the signature against a curated synovial reference panel (GSE55235, GSE89408, GSE77298).** Highest priority because the gene content is tissue-incongruent (mucins, CROCC, GRIFIN, GJC2). Without this, every downstream conclusion is at risk. **Hypothesis class: confounding/composition check. Status: supported hypothesis** (that tissue composition is driving the signature).

2. **Mechanistic — Validate Hippo/PCP-axis transcript loss in RA fibroblast-like synoviocytes (FLS).** qPCR/IHC of SCRIB, ARVCF, APC2, ARHGAP33 in sorted CD45⁻PDPN⁺ FLS from RA vs. OA vs. normal synovium. **Status: exploratory hypothesis** (no internal mechanistic claim yet, but multiple genes in the set support it).

3. **Biomarker — Test whether the mucin (MUC5B/MUC6/MUC12) + ciliary (CROCC/CROCC2) loss is detectable in synovial fluid cell-free RNA or in serum.** If the downregulation is reproducible across cohorts, a *ratio* signature could distinguish RA from non-RA synovial pathology. **Status: exploratory hypothesis** — the absence of inflammatory markers in the same dataset undermines specificity claims.

4. **Interaction/network hypothesis — Test SCRIB–CTNNB1–ARVCF co-regulation in RA FLS.** STRING evidence is high-confidence for SCRIB's interactors and medium-confidence for ARVCF↔CTNNB1; whether this complex is co-downregulated at the protein level in RA is unknown. Co-IP and proximity ligation in primary FLS would be the appropriate next step. **Status: exploratory hypothesis.**

5. **Therapeutic target / Biomarker — Evaluate CBX7 (PRC1) loss as an epigenetic vulnerability in RA FLS.** CBX7 is a Polycomb component whose loss may de-repress senescence/inflammatory genes. This is **mechanistic** and **exploratory**, and is *not* an established therapeutic target; the mere existence of PRC1 inhibitors does not validate CBX7 as a tractable RA target.

---

## 5. Evidence Grounding — Summary Table

| Program | Direct dataset evidence | Pathway / ontology | Protein / regulatory network | Tissue / expression | Disease / genetic | Drug / therapeutic | Literature |
|---|---|---|---|---|---|---|---|
| A. Mucin loss | 3 genes, FDR <1e-39 | Weak (generic) | STRING mucin hubs (co-annotation) | GTEx: mucins = mucosal tissues (context-mismatch with synovium) | OpenTargets/ClinVar: weak RA link | None specific | None RA-specific |
| B. PCP/Hippo | 10+ genes, FDR <1e-37 | KEGG Hippo; GO PCP/ciliary | STRING: SCRIB high-conf; ARVCF med-conf; APC2/CROCC co-membership | GTEx: SCRIB/APC2 broadly expressed; CROCC ciliated-cell enriched | OpenTargets: no strong RA genetic signal | None specific | None RA-specific |
| C. Apoptosis | 2 genes | GO apoptosis | STRING CASP2 hub (co-membership) | Broad | None specific | None specific | None RA-specific |
| D. ncRNAs | 20+ loci | GO ncRNA | None direct | None synovial-specific | None | None | MIR647 = NSCLC, not RA (context-mismatch) |
| E. TF/chromatin | 12 genes | GO protein binding/nucleus | Limited | Broad | None | None | None |

**Independence caveat:** Pathway/ontology and STRING co-membership records share underlying annotation databases (Reactome/QuickGO/STRING all draw on shared ontologies and literature); they are **not** independent evidence for the same claim.

**No source provides independent cohort-level replication** of these effect sizes. Pathway, network, and literature records are contextual only.

---

## 6. Limitations and Alternative Explanations

1. **Tissue/cell-composition mismatch.** The mucin, ciliary, and lens-protein (GRIFIN) components are inconsistent with synovial identity and suggest the "normal" comparator includes cell types not present in RA synovium (or the RA samples are depleted of a specialized lining/fibroblast subset). This must be addressed by **deconvolution** (CIBERSORTx, MuSiC) against synovial scRNA references before any mechanistic claim is made.

2. **Absence of canonical RA inflammatory signature.** RA synovial tissue is expected to show strong upregulation of IL6, TNF, IL1B, CCL2, MMP1/3/13, CXCL8/10. Their absence here is itself a major data-quality signal — possible causes include (a) RNA-seq library bias/depletion of highly expressed transcripts, (b) comparator swap, (c) inclusion of low-inflammation samples only. **Re-running the differential analysis with the original full count matrix is the appropriate diagnostic step.**

3. **Monodirectionality and uniform extreme significance.** All 100 genes downregulated, all with FDR < 4.3e-35 — this is unusual and may reflect (a) a sample outlier, (b) normalization artefact (e.g., DESeq2 size factors driven by one high-library sample), or (c) genuine loss of a large coordinated transcriptional module. **Diagnostic:** inspect PCA/MDS, library sizes, and dispersion.

4. **Treatment exposure and disease stage not declared.** RA patients on DMARDs, steroids, or biologics show altered synovial transcriptomes; without covariate adjustment, downregulated signatures can reflect therapy rather than disease biology.

5. **Batch/platform effects.** Cross-platform integration of synovial microarrays vs. RNA-seq is a known source of systematic biases for mucins, ncRNAs, and structural transcripts — particularly for the LOC/unannotated loci that dominate this list.

**General principle applied:** no association is presented as causal; no drug-target annotation is treated as therapeutic evidence; no annotation-source record count is treated as replication strength. The signature's internal statistics are coherent, but its biological interpretation is held back until tissue-composition and inflammatory-marker sanity checks are performed.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=0, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 84/100 selected items (records returned); cbioportal 82/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 19/100 selected items (records returned); clinvar 79/100 selected items (records returned); ensembl 40/100 selected items (partially returned; some queries failed); europepmc 776 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 61/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 47/100 selected items (records returned); humanbase 88/100 selected items (partially returned; some queries failed); intact 47/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 17/100 selected items (records returned); opentargets 82/100 selected items (records returned); pubmed 483 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 50/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 51/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 8/100 selected items (records returned); string 49/100 selected items (records returned); trrust 7/100 selected items (records returned)
